European Academy of Allergy and Clinical Immunology

Non-invasive skin immune biomarker test helps predict development of eczema in babies, new study presented at the EADV Congress finds

Retrieved on: 
Tuesday, September 6, 2022
University, Bispebjerg Hospital, Shoulder, Dermatitis, Disease, Skin, Barrier, BABY, TARC, Association, European Academy of Allergy and Clinical Immunology, IT University of Copenhagen, Immune system, Population, Biomarker, Risk, Congress, Life, Journal of the European Academy of Dermatology and Venereology, Pharmaceutical industry, Vaccine, Medical device, Venereology, Dermatology

MILAN, Sept. 6, 2022 /PRNewswire/ -- Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown.

Key Points: 
  • MILAN, Sept. 6, 2022 /PRNewswire/ -- Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown.
  • The study found a positive association between the level of TARC and the severity of eczema.
  • The strips were analysed for immune biomarkers and babies were followed up for the next 2 years.
  • This provides a window of opportunity to develop targeted trials and prevent cases of eczema from occurring", concluded Dr Anne-Sofie Halling.

Non-invasive skin immune biomarker test helps predict development of eczema in babies, new study presented at the EADV Congress finds

Retrieved on: 
Tuesday, September 6, 2022
University, Bispebjerg Hospital, Shoulder, Dermatitis, Disease, Skin, Barrier, BABY, TARC, Association, European Academy of Allergy and Clinical Immunology, IT University of Copenhagen, Immune system, Population, Biomarker, Risk, Congress, Life, Journal of the European Academy of Dermatology and Venereology, Pharmaceutical industry, Vaccine, Medical device, Venereology, Dermatology

MILAN, Sept. 6, 2022 /PRNewswire/ -- Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown.

Key Points: 
  • MILAN, Sept. 6, 2022 /PRNewswire/ -- Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown.
  • The study found a positive association between the level of TARC and the severity of eczema.
  • The strips were analysed for immune biomarkers and babies were followed up for the next 2 years.
  • This provides a window of opportunity to develop targeted trials and prevent cases of eczema from occurring", concluded Dr Anne-Sofie Halling.

Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial

Retrieved on: 
Monday, August 29, 2022
AES, COVID-19, Technology, Safety, Research, University, Penn, A4, Real-time, U.S. Securities and Exchange Commission, GLOBE, Company, Adult, Risk, Congress, Patient, Neurotoxicity, Glomerulonephritis, CRS, Immunity, Incidence, Biopsy, Pemphigus, Immunoglobulin therapy, MPV, Mitsubishi A6M Zero, Annual report, Cyclophosphamide, Security (finance), Poster, Infrared spectroscopy correlation table, Form 10-K, Degenerative disease, CAR, Haemophilia, Disease, LinkedIn, Perelman School of Medicine at the University of Pennsylvania, Cytokine release syndrome, Private Securities Litigation Reform Act, Health, European Academy of Allergy and Clinical Immunology, Infection, MuSK protein, ELISA, CEST, University of Pennsylvania, Pharmaceutical industry, A5, Venereology, Cabaletta, Dermatology

The DesCAARTes Phase 1 trial is an open-label, dose escalation, multi-center study of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV).

Key Points: 
  • The DesCAARTes Phase 1 trial is an open-label, dose escalation, multi-center study of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV).
  • "The totality of the data generated to date from the DesCAARTes trial has provided important insights that have guided our efforts to enhance in vivo DSG3-CAART exposure.
  • The University of Pennsylvania may also receive future financial benefit under licenses it has granted to Cabaletta Bio.
  • All information in this press release is as of the date of the release, and Cabaletta undertakes no duty to update this information unless required by law.

LEO Pharma to present new data in moderate-to-severe atopic dermatitis and chronic hand eczema at the 31st EADV Congress

Retrieved on: 
Thursday, August 25, 2022
Health, Pharmaceutical, Janus, Tralokinumab, Jake Virtanen, Systematic review, JT, Safety, Pain, Research, Atopic dermatitis, Ageing, Swelling, United Arab Emirates, BioDrugs, Disease, Itch, Autoimmune disease, JAAD, Diagnosis, Science, Poster, HE, Blister, DKK, Annual general meeting, European Academy of Allergy and Clinical Immunology, Immune system, Prevalence, CHE, Thyssen, Adult, AD, Epidemiology, Congress, JAK, Leo Pharma, Journal of the European Academy of Dermatology and Venereology, Patient, Vaccine, Pharmaceutical industry, Medical device, Hospital, Venereology, EU, Veni, vidi, vici, Dermatology

LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.

Key Points: 
  • LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.
  • 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis.
  • Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest.
  • Safety of tralokinumab in paediatric patients aged 12-17 with moderate-to-severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial.

LifeMD and Cleared Offer New Hope to Allergy Patients Through Strategic Partnership With Allergenis

Retrieved on: 
Monday, August 22, 2022
Partnership, EAACI, Patient, Epitope mapping, Security (finance), CEO, Food, Securities Exchange Act of 1934, Caregiver, Securities Act of 1933, NASDAQ, Peanut allergy, Food allergy, Overalls, Parent, Drug Quality and Security Act, Blood, Standard of care, Anxiety, LinkedIn, Asthma, Diagnosis, Mount Sinai, Forward-looking statement, Icahn School of Medicine at Mount Sinai, Journal, U.S. Securities and Exchange Commission, Immunology, CLIA, European Academy of Allergy and Clinical Immunology, GLOBE, Instagram, Database, JAMA Pediatrics, Clear, Company, OFC, Twitter, News, LFMD, Risk, Terminology, Annual report, Private Securities Litigation Reform Act, Review, Marketing, William Frankland (allergist), Child, Â, Medical device, Vaccine, Health insurance, Hospital, Risk management, Medicine, Allergy, Facebook

The strategic partnership leverages Cleareds direct-to-patient allergy telehealth infrastructure and marketing expertise and Allergenis breakthrough peanut allergy diagnostic blood test.

Key Points: 
  • The strategic partnership leverages Cleareds direct-to-patient allergy telehealth infrastructure and marketing expertise and Allergenis breakthrough peanut allergy diagnostic blood test.
  • The partnership also establishes Cleared as the exclusive telehealth provider for the commercial launch of Allergenis highly accurate peanut allergy diagnostic in the direct-to-consumer channel.
  • The partnership sets a new standard in food allergy management with Allergenis novel, low-risk and non-invasive peanut allergy diagnostic blood test.
  • The Allergenis peanut allergy diagnostic is potentially life-changing for food allergy patients, who have had to rely on a potentially risky and often anxiety-producing procedure called an oral food challenge to rule out a food allergy, said LifeMD CEO Justin Schreiber.

ASLAN Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, August 12, 2022
Autoimmune disease, Biomarker, Johns Hopkins School of Medicine, Pediatrics, Inflammatory bowel disease, CEO, European Academy of Allergy and Clinical Immunology, GLOBE, 2021 Essex County Council election, R, ADS, Aspect, Investment, American depositary receipt, Congress, Research, Research and development, Patient, Company, ASLN, Society, Northwestern University, A4, KOL, Atopic dermatitis, AD, DHODH, Duke University Hospital, Nasdaq, SID, Cryptocurrency, Pharmaceutical industry, Dermatology, Venereology

MENLO PARK, Calif. and SINGAPORE, Aug. 12, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the second quarter ended June 30, 2022, and provided an update on recent corporate activities.

Key Points: 
  • Cash used in operating activities for the second quarter of 2022 was US$9.7 million compared to US$6.9 million in the same period in 2021.
  • Research and development expenses were US$10.0 million in the second quarter of 2022 compared to US$4.0 million in the second quarter of 2021.
  • General and administrative expenses were US$2.3 million in the second quarter of 2022 compared to US$3.8 million in the second quarter of 2021.
  • Net loss attributable to stockholders for the second quarter of 2022 was US$13.0 million compared to a net loss of US$5.4 million for the second quarter of 2021.

ASLAN Pharmaceuticals Announces Three Abstracts Highlighting New Eblasakimab Data Have Been Accepted as E-Posters at the 31st European Academy of Dermatology and Venereology (EADV) Congress

Retrieved on: 
Thursday, August 11, 2022
Serum, Journal of the European Academy of Dermatology and Venereology, Biomarker, Investor relations, European Academy of Allergy and Clinical Immunology, GLOBE, 2021 Essex County Council election, Congress, Patient, ASLN, Autoimmune disease, Safety, NASDAQ, Atopic dermatitis, AD, DHODH, Nasdaq, Sleep, LinkedIn, Time, Adult, Pharmaceutical industry, Vaccine, Dermatology, Venereology

The posters will be available to view online in the Investor Relations section of ASLANs website following presentation: https://ir.aslanpharma.com/ .

Key Points: 
  • The posters will be available to view online in the Investor Relations section of ASLANs website following presentation: https://ir.aslanpharma.com/ .
  • In September 2021, ASLAN announced positive results from the Phase 1b multiple-ascending-dose study that established proof-of-concept of ASLAN004 and supported its potential as a novel treatment for AD.
  • In January 2022, ASLAN initiated the TREK-AD Phase 2b trial to evaluate the safety and efficacy of eblasakimab in moderate-to-severe AD patients.
  • ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients.

Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Tuesday, August 9, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, FDA, Risk, Drug discovery, Forward-looking statement, European Academy of Allergy and Clinical Immunology, Drug, Half-life, SEC, Investment, Facebook, Disease, Annual report, Plasma, Patient, Review, Instagram, Therapy, COVID-19, Company, Twitter, D, Pharmacy, Neonatal Fc receptor, Safety, Plasma kallikrein, NASDAQ, Research, Food and Drug Administration Amendments Act of 2007, Hereditary angioedema, Allergy, Human, LinkedIn, Time, Conference, Food, Pharmacokinetics, Pharmaceutical industry, Online gambling, Aquaculture, Tutoring, HAE

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.
  • We expect preliminary results from the Phase 1a trial by the end of this year.
  • The Food and Drug Administration cleared Astrias Investigational New Drug application for STAR-0215 and the company initiated a Phase 1a clinical trial with preliminary results anticipated by year-end 2022.
  • Dr. Morabito brings more than 20 years of clinical development experience in rare diseases and other indications to Astria.

Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 8, 2022
SRS, Survival, GLOBE, R, CSU, Clinical trial, Cancer, Cold urticaria, Knowledge, Research, Patient, Pembrolizumab, Skin, G&A, Loss, Immune system, EAACI, EOE, Private Securities Litigation Reform Act, Hector Avalos, Eosinophilic esophagitis, Allergy, B cell, Form 10-K, Rockefeller University, Biotechnology, Contingency (philosophy), UAS7, Ovarian cancer, Omalizumab, Intellectual property, Term sheet, Forward-looking statement, European Academy of Management, CD27, Hypersensitivity, Itchy, Gilead Sciences, Therapy, COVID-19, Cell, Large-cell lung carcinoma, D, Judgement, SCCHN, Â, Goal, Time, Annual report, SD, Antibody, KIT, Inflammation, Metabolic pathway, Prurigo nodularis, CD40, Hives, European Academy of Allergy and Clinical Immunology, Company, Risk, NASDAQ, Consultant, Pharmaceutical industry, Vaccine, Aluminium, Palladium

HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Key Points: 
  • HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
  • Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.
  • In June 2022, Cheryl L. Cohen and Dr. Garry Neil were appointed to the Celldex Board of Directors.
  • The decrease was primarily driven by second quarter cash used in operating activities of $22.2 million.

Astria Therapeutics Presents New Preclinical Data Showing Differentiated Profile of STAR-0215, in Development for Treatment of Hereditary Angioedema

Retrieved on: 
Tuesday, July 5, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Plasma kallikrein, Review, Immunology, FDA, HAE, Annual report, Demonstration, Patient, LinkedIn, Treatment, Plasma, Allergy, Hereditary angioedema, COVID-19, Company, Pharmacy, Risk, European Academy of Allergy and Clinical Immunology, Drug discovery, Half-life, SEC, Facebook, Human, NASDAQ, HMWK, Instagram, Time, Twitter, Therapy, Forward-looking statement, Pharmaceutical industry, Asteria

The study, conducted in cynomolgus monkeys, showed rapid inhibition of plasma kallikrein after subcutaneous administration.

Key Points: 
  • The study, conducted in cynomolgus monkeys, showed rapid inhibition of plasma kallikrein after subcutaneous administration.
  • Inhibition of HMWK cleavage was rapid and sustained throughout an 84-day dose-free period in the extended portion of the study.
  • These data confirm the long half-life of STAR-0215 and demonstrate prolonged pharmacological activity of STAR-0215 in circulation in cynomolgus monkeys.
  • Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.